We are live on
!
Find out more
FGP
Foyston, Gordon, & Payne Portfolio holdings
AUM
$468M
Turnover
12.5%
1-Year Est. Return
6.67%
This Fund
S&P 500
This Quarter
Est. Return
+5.05%
1 Year Est. Return
+6.67%
3 Year Est. Return
+57.25%
5 Year Est. Return
+83.16%
10 Year Est. Return
+253.32%
AUM
$787M
AUM Growth
-$24.3M
(-3%)
Cap. Flow
-$58.4M
Cap. Flow
% of AUM
-7.41%
Top 10 Holdings %
Top 10 Hldgs %
35.43%
Holding
86
New
1
Increased
12
Reduced
49
Closed
5
Avg Time Held
0.9
years
Top 10 Avg Time Held
0.6
years
Top 20 Avg Time Held
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$16M |
| 2 |
Medtronic
MDT
|
+$6.22M |
| 3 |
Knowles
KN
|
+$4.68M |
| 4 |
Baxter International
BAX
|
+$4.2M |
| 5 |
Shinhan Financial Group
SHG
|
+$734K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 2000 ETF
IWM
|
+$13.5M |
| 2 |
Ryder
R
|
+$5.64M |
| 3 |
ICICI Bank
IBN
|
+$4.68M |
| 4 |
Jabil
JBL
|
+$4.55M |
| 5 |
BHI
Baker Hughes
BHI
|
+$4.14M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.58% |
| 2 | Technology | 15.83% |
| 3 | Financials | 15.07% |
| 4 | Energy | 11.76% |
| 5 | Consumer Staples | 9.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Norfolk Southern
NSC
$73.4B
| $12.7M | 1.61% |
123,225
-7,490
| -6% | -$735K |
2013 Q2
4 quarters
|
|
27
PPL Corp
PPL
$26.5B
| $11.7M | 1.48% |
353,256
-25,662
| -7% | -$809K |
2013 Q2
4 quarters
|
|
28
ConocoPhillips
COP
$176B
| $11.4M | 1.45% |
133,458
-14,210
| -10% | -$1.11M |
2013 Q2
4 quarters
|
|
29
CSX Corp
CSX
$90.2B
| $10.5M | 1.34% |
1,026,642
-4,287
| -0.4% | -$41.7K |
2013 Q2
4 quarters
|
|
30
Abercrombie & Fitch
ANF
$6.5B
| $10.4M | 1.32% |
239,519
-26,929
| -10% | -$1.04M |
2013 Q4
2 quarters
|
|
31
Merck
MRK
$360B
| $10.1M | 1.29% |
183,758
-50,409
| -22% | -$2.75M |
2013 Q2
4 quarters
|
|
32
Teradata
TDC
$2.82B
| $9.87M | 1.25% |
245,545
-750
| -0.3% | -$32.7K |
2013 Q4
2 quarters
|
|
33
Amdocs
DOX
$6.27B
| $9.65M | 1.23% |
208,390
-6,590
| -3% | -$310K |
2013 Q2
4 quarters
|
|
34
Stanley Black & Decker
SWK
$14B
| $9.64M | 1.22% |
109,720
-6,430
| -6% | -$548K |
2013 Q4
2 quarters
|
|
35
Telefônica Brasil
VIV
$20B
| $9.58M | 1.22% |
467,217
-36,479
| -7% | -$753K |
2013 Q3
3 quarters
|
|
36
Molson Coors Class B
TAP
$7.37B
| $9.38M | 1.19% |
126,501
-1,560
| -1% | -$101K |
2013 Q2
4 quarters
|
|
37
Ford
F
$49.6B
| $9.26M | 1.18% |
537,199
-24,200
| -4% | -$394K |
2013 Q4
2 quarters
|
|
38
Mattel
MAT
$4.91B
| $9.24M | 1.17% |
237,062
-6,210
| -3% | -$241K |
2014 Q1
1 quarter
|
|
39
Hancock Whitney
HWC
$5.86B
| $8.36M | 1.06% |
236,653
-8,580
| -3% | -$296K |
2013 Q2
4 quarters
|
|
|
40
Knowles
KN
$2.86B
| $8.34M | 1.06% |
271,289
+154,630
| +133% | +$4.68M |
2014 Q1
1 quarter
|
|
41
Devon Energy
DVN
$55.8B
| $8.13M | 1.03% |
102,327
-29,043
| -22% | -$2.11M |
2013 Q2
4 quarters
|
|
42
Cardinal Health
CAH
$58.8B
| $7.5M | 0.95% |
109,372
-17,020
| -13% | -$1.16M |
2013 Q2
4 quarters
|
|
43
Tapestry
TPR
$23.8B
| $7.36M | 0.93% |
215,274
+3,593
| +2% | +$154K |
2013 Q2
4 quarters
|
|
44
DELISTED
Du Pont De Nemours E I
DD
| $7.28M | 0.92% |
117,122
-27,157
| -19% | -$1.75M |
2013 Q2
4 quarters
|
|
|
PTR
45
DELISTED
PETROCHINA COMPANY LIMITED ADS (REP 100 H SHARES)
PTR
| $6.73M | 0.85% |
53,570
-3,224
| -6% | -$380K |
2013 Q3
3 quarters
|
|
46
Sanofi
SNY
$97.3B
| $5.33M | 0.68% |
100,179
+1,216
| +1% | +$64.5K |
2013 Q3
3 quarters
|
|
47
Sabesp
SBS
$22B
| $4.84M | 0.61% |
2,327,943
-44,986
| -2% | -$86.2K |
2013 Q3
3 quarters
|
|
|
RDS.A
48
DELISTED
Royal Dutch Shell PLC ADS Class A
RDS.A
| $4.71M | 0.6% |
61,181
-998
| -2% | -$72.9K |
2013 Q3
3 quarters
|
|
49
Prudential
PUK
$29.6B
| $4.67M | 0.59% |
104,870
+642
| +0.6% | +$28.5K |
2013 Q3
3 quarters
|
|
50
KT
KT
$8.74B
| $4.62M | 0.59% |
305,189
+27,697
| +10% | +$421K |
2013 Q3
3 quarters
|
|
Similar funds
GC
SCP
THC
STCG
BAM
TOCUITCONY
MB
TAM
Foyston, Gordon, & Payne's Q2 2014 Portfolio in Review
As of Q2 2014, Foyston, Gordon, & Payne held 86 positions worth $787M, down 3% from $812M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Foyston, Gordon, & Payne withdrew a net $58.4M in Q2 2014, closing 5 positions and reducing 49 holdings. Its most notable exit was iShares Russell 2000 ETF, an estimated $13.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, up from 20% a quarter earlier, followed by Technology and Financials.
Against the trend, Foyston, Gordon, & Payne opened a new position in Compañía de Cervecerías Unidas worth $693K.
- Foyston, Gordon, & Payne's largest Q2 2014 buy was Compañía de Cervecerías Unidas: 29,600 shares worth $693K.
- Foyston, Gordon, & Payne added most to Teva Pharmaceutical Industries Limited in Q2 2014, an estimated $16M increase.
- Foyston, Gordon, & Payne's biggest Q2 2014 reduction was Ryder, cutting an estimated $5.64M.
- Foyston, Gordon, & Payne fully exited iShares Russell 2000 ETF in Q2 2014, selling an estimated $13.5M.
- Foyston, Gordon, & Payne's ten largest holdings make up 35% of its $787M portfolio in Q2 2014.
- Foyston, Gordon, & Payne opened 1 new position and closed 5 in Q2 2014.
- Foyston, Gordon, & Payne's portfolio value fell 3% quarter-over-quarter to $787M.
Based on Foyston, Gordon, & Payne's 13F filing for Q2 2014, filed 14 Aug 2014.